BTX-A51

A First-In-Human, Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX-A51 Capsules Alone and in Combination With Azacitidine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Arms / Cohorts

Experimental: Monotherapy Cohort Escalation:Part 1a: BTX-A51 - AML Patients

Accepting patients

Experimental: Monotherapy Cohort Escalation:Part 1a: BTX-A51 - MDS Patients

Accepting patients

Experimental: Monotherapy Cohort Expansion:Part 1b: BTX-A51 - AML Patients

Accepting patients

Experimental: Monotherapy Cohort Expansion:Part 1b: BTX-A51 - MDS Patients

Accepting patients

Experimental:Part 1c: BTX-A51 + Azacitidine - AML Patients

Accepting patients

Experimental:Part 1c: BTX-A51 + Azacitidine - MDS Patients

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.